HCV Treatment Lags: CDC Vital Signs

TargetHIV

A majority of people diagnosed with hepatitis C virus (HCV) are not being treated with highly effective and curative direct-acting antivirals (DAA), according to a an August 2022 CDC sample report. 

Vital Signs: Hepatitis C Treatment Among Insured Adults — United States, 2019–2020, a sample study, found that, at most, only one-third of those diagnosed with HCV subsequently start DAA therapy within a year of their diagnosis, with lower DAA treatment rates among those with Medicaid and Medicare coverage as compared to those with private health insurance.

Following are select resources for clinicians and agencies on the maze of coverage restrictions and requirements and treatment models for consideration. 

Start with the basics at the CDC Viral Hepatitis webpage, with a robust section, Hepatitis C Questions and Answers for Health Professionals.

We'd like your feedback

Was this page helpful?
I found this page helpful because the content on the page:
Check all that apply
I did not find this page helpful because the content on the page:
Check all that apply
Please include an email address if you would like a response
Please include an email address if you would like a response
Did you use this approach in your work?
Not yet because
If no, why not?